Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy

Inclusion Criteria: * Histological diagnosis of locally advanced or metastatic pancreatic cancer (except neuroendocrine tumors, but including ampullary cancer) with progression after standard first line therapy that included gemcitabine (single agent or combination) * Measurable disease on computated tomography (CT) scan per Response Evaluation Criteria in Solid Tumors (RECIST) criteria * At least 28 days from previous systemic therapy, including investigational agents and 1st dose of study treatment and recovered from any acute toxic effects of that treatment before study enrollment. * Has Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1 - Ability to provide written consent * Must meet hematology and biochemistry laboratory criteria within 14 days of study enrollment: * Neutrophil count \>1500/mm\^3 * Platelet count \>100,000/mm\^L * Hemoglobin \> or = 9 g/dL * Aspartate aminotransferase (AST/SGOT) or Alanine transaminase (ALT/SGPT) \< or = 2.5 times upper limit of normal (ULN)or ≤ 5.0 x ULN if the transaminase elevation is due to disease involvement * Serum bilirubin \< or = 1.5 x ULN * Serum creatinine \< or = 1.5 x ULN or 24-hour creatinine clearance ≥ 50 ml/min * Total serum calcium (corrected for serum albumin) or ionized calcium ≥ lower limit of normal (LLN) * Serum phosphorus \> or = LLN * Serum potassium \> or = LLN * Serum sodium ≥ LLN * Serum magnesium ≥ LLN * Serum albumin ≥ LLN or 3g/dl * Patients with any elevated A…